O
Onconova Therapeutics
Discovering and developing novel small molecule drug candidates to treat cancer
About Onconova Therapeutics
Onconova Therapeutics, Inc. is a Phase 3 clinical stage biopharmaceutical company dedicated to discovering and developing novel small molecule drug candidates aimed at treating cancer. The company leverages a proprietary chemistry platform to create a pipeline of targeted anti-cancer agents designed to interfere with specific cellular pathways crucial to cancer cells, while minimizing harm to normal cells. Onconova's primary clients include healthcare providers and institutions involved in cancer treatment and research. Operating in the biopharmaceutical market, Onconova's business model revolves around advancing its drug candidates through clinical trials, securing regulatory approvals, and ultimately commercializing these therapies. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved drugs.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2013
News
Open roles
Onconova Therapeutics in the Newtown ecosystem
The Onconova Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Lincoln Park Capital Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Onconova Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Onconova Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


